

Production scientifique AGIR 2021

I) Brevets Ø

II) Publications internationales

(P2021-01) Management of drug toxicity in *M. avium* complex pulmonary disease - an expert panel survey

J. van Ingen, S. Aliberti, C. Andrejak, J.-D. Chalmers, L.-R. Codecasa, C.-L. Daley, N. Hasegawa, D.-E. Griffith, W. Hoefsloot, G. Huitt, J. Jarand, B.-W. Jhun, M.-R. Loebinger, T.-K. Marras, L. Morimoto, E. Polverino, F.-C. Ringshausen, M. Santin, R. Thomson, D. Wagner, R.-J. Wallace, K.-L. Winthrop, J.-J. Yim

Clin. Infect. Dis. 2021, 73(1), e256-e259; doi: 10.1093/cid/ciaa1361.

(P2021-02) Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19

B. Batteux, S. Bodeau, V. Gras-Champel, S. Liabeuf, J.-P. Lanoix, J.-L. Schmit, C. Andrejak, Y. Zerbib, G. Haye, K. Masmoudi, A.-S. Lemaire-Hurtel, Y. Bennis.

Br. J. Clin. Pharmacol. 2021, 87(3), 1547-1553; doi: 10.1111/bcp.14489.

(P2021-03) Medical versus surgical treatment in native hip and knee septic arthritis

C. Mabillet, Y. El Samad, C. Joseph, B. Brunschweiler, V. Goeb, F. Grados, J.-P. Lanoix
Infect. Dis. Now 2021, 51(2), 164-169.

(P2021-04) The association between body mass index class and coronavirus disease 2019 outcomes

A. Al-Salameh, J.-P. Lanoix, Y. Bennis, C. Andrejak, E. Brochot, G. Deschasse, H. Dupont, V. Goeb, M. Jauregui, S. Lion, J. Maizel, J. Moyet, B. Vaysse, R. Desaillood, O. Ganry, J.-L. Schmit, J.-D. Lalau
Int. J. Obes. 2021, 45, 700-705; doi: 10.1038/s41366-020-00721-1.

(P2021-05) Hypoxemia and prone position in mechanically ventilated COVID-19 patients: a prospective cohort study

O. Abou-Arab, G. Haye, C. Beyls, P. Huet, P.-A. Roger, M. Guilbart, M. Bernasinski, P. Besserve, F. Trojette, H. Dupont, V. Jounieaux, Y. Mahjoub

Can. J. Anaesth. 2021, 68(2), 262-263; doi: 10.1007/s12630-020-01844-9.

(P2021-06) Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes

A. Al-Salameh, J.-P. Lanoix, Y. Bennis, C. Andrejak, E. Brochot, G. Deschasse, H. Dupont, V. Goeb, M. Jauregui, S. Lion, J. Maizel, J. Moyet, B. Vaysse, R. Desaillood, O. Ganry, J.-L. Schmit, J.-D. Lalau
Diabetes Metab. Res. Rev. 2021, 37(3), e3388; doi: 10.1002/dmrr.3388.

(P2021-07) First case of *Kingella kingae* spondylodiscitis in an elderly man with a molecular characterization of the responsible strain

M. Doussiere, M. Choquet, F. Grados, F. Peltier, J.-P. Lanoix, V. Goëb

Infect. Dis. Now 2021, 51(5), 497-499; doi: 10.1016/j.idnow.2020.10.003.

(P2021-08) Antimicrobial peptide K11 selectively recognizes bacterial biomimetic membranes and acts by twisting their bilayers

F. Ramos-Martín, C. Herrera-León, V. Antonietti, P. Sonnet, C. Sarazin, N. D'Amelio

Pharmaceuticals 2021, 14, 1; doi: 10.3390/ph14010001.

(P2021-09) Longitudinal analysis and comparison of six serological assays up to eight months post-COVID-19 diagnosis

A. Aubry, B. Demey, C. François, G. Duverlie, S. Castelain, F. Helle, E. Brochot

J. Clin. Med. 2021, 10(9), 1815; doi: 10.3390/jcm10091815.

(P2021-10) Safety and efficacy of pirpenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related dene mutation

A. Justet, D. Klay, R. Porcher, V. Cottin, K. Ahmad, M. Molina Molina, H. Nunes, M. Reynaud-Gaubert, J.-M. Naccache, E. Manali, A. Froidure, S. Jouneau, L. Wemeau, C. Andrejak, A. Gondouin, S. Hirschi, E. Blanchard, B. Bondue, P. Bonniaud, C. Tromeur, G. Prévot, S. Marchand-Adam, M. Funke-Chambour, A.-S. Gamez, I. Ba, S. Papiris, J. Grutters, B. Crestani, C. van Moorsel, C. Kannengiesser, R. Borie

Eur. Respir. J. 2021, 57(2), 2003198; doi: 10.1183/13993003.03198-2020.

(P2021-11) Management of drug toxicity in *Mycobacterium avium* complex pulmonary disease: an expert panel survey

J. van Ingen, S. Aliberti, C. Andrejak, J.-D. Chalmers, L.-R. Codecasa, C.-L. Daley, N. Hasegawa, D.-E. Griffith, W. Hoefsloot, G. Huitt, J. Jarand, B.-W. Jhun, M.-R. Loebinger, T.-K. Marras, K. Morimoto, E. Polverino, F.-C. Ringshausen, M. Santin, R. Thomson, D. Wagner, R.-J. Wallace, K.-L. Winthrop, J.-J. Yim

Clin. Infect. Dis. 2021, 73(1), e256-e259; doi: 10.1093/cid/ciaa1361.

(P2021-12) Pure SARS-CoV-2 related AVDS (Acute Vascular Distress Syndrome)

V. Jounieaux, D. Basille, O. Abou-Arab, M.-P. Guillaumont, C. Andrejak, Y. Mahjoub, D.-O. Rodenstein
BMC Infect. Dis. 2021, 21(1), 122; doi: 10.1186/s12879-021-05805-5.

(P2021-13) Randomised trial of first-line bronchial artery embolisation for non-severe haemoptysis of mild abundance

M. Fartoukh, A. Demoule, O. Sanchez, S. Tuffet, E. Bergot, C. Godet, C. Andrejak, S. Pontier-Marchandise, A. Parrot, J. Mayaux, G. Meyer, P. Cluzel, M. Sapoval, V. Le Pennec, M.-F. Carette, J. Cadranel, A. Rousseau, A. Khalil, T. Simon; ARTEMHYS trial group

BMJ Open Respir. Res. 2021, 8(1), e000949; doi: 10.1136/bmjresp-2021-000949.

(P2021-14) A simple score (biovid-19) based on biological parameters predicts transfer to intensive care units and death in COVID-19 patients

C. Sauzay, G. Couillez, M. Le Guyader, O. Evrard, R. Nyga, J.-L. Schmit, C. Andréjak, C. François, S. Castelain, J. Maizel, L. Garçon, E. Brochot, A. Caulier, T. Boyer

Curr. Res. Transl. Med. 2021, 69(2), 103284; doi: 10.1016/j.retram.2021.103284.

(P2021-15) Dissociation between the clinical course and chest imaging in severe COVID-19 pneumonia: a series of five cases

D. Basille, M.-A. Auquier, C. Andréjak, D.-O. Rodenstein, Y. Mahjoub, V. Jounieaux; A&P Group

Heart Lung. 2021, 50(6), 818-824; doi: 10.1016/j.hrtlng.2021.06.008.

(P2021-16) An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19

F. Ader, N. Peiffer-Smadja, J. Poissy, M. Bouscambert-Duchamp, D. Belhadi, A. Diallo, C. Delmas, J. Saillard, A. Dechanet, N. Mercier, A. Dupont, T. Alfaiate, F.-X. Lescure, F. Raffi, F. Goehringer, A. Kimmoun, S. Jaureguiberry, J. Reignier, S. Nseir, F. Danion, R. Clere-Jehl, K. Bouiller, J.-C. Navellou, V. Tolsma, A. Cabié, C. Dubost, J. Courjon, S. Leroy, J. Mootien, R. Gaci, B. Mourvillier, E. Faure, V. Pourcher, S. Gallien, O. Launay, K. Lacombe, J.-P. Lanoix, A. Makinson, G. Martin-Blondel, L. Bouadma, E. Botelho-Nevers, A. Gagneux-Brunon, O. Epaulard, L. Piroth, F. Wallet, J.-C. Richard, J. Reuter, T. Staub, B. Lina, M. Noret, C. Andrejak, M.-P. Lê, G. Peytavin, M. Hites, D. Costagliola, Y. Yazdanpanah, C. Burdet, F. Mentré; DisCoVeRy study group

Clin. Microbiol. Infect. 2021, 27(12), 1826-1837; doi: 10.1016/j.cmi.2021.05.020.

(P2021-17) BK polyomavirus micro-RNAs : time course and clinical relevance in kidney transplant recipients

B. Demey, V. Descamps, C. Presne, F. Helle, C. François, G. Duverlie, S. Castelain, E. Brochot

Viruses 2021, 13(2), 351; doi: 10.3390/v13020351.

(P2021-18) Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France

T. Woudenberg, S. Pelleau, F. Anna, M. Attia, F. Donnadieu, A. Gravet, C. Lohmann, H. Seraphin, R. Guiheneuf, C. Delamare, K. Stefic, J. Marlet, E. Brochot, S. Castelain, O. Augereau, J. Sibilis, F. Dubos, D. Meddour, C.-G. Guen, M. Coste-Burel, B.-M. Imbert-Marcille, A. Chauvire-Drouard, C. Schweitzer, A. Gatin, S. Lomazzi, A. Joulie, H. Haas, A. Cantais, F. Bertholon, M.-F. Chinazzo-Vigouroux, M.-S. Abdallah, L. Arowas, P. Charneau, B. Hoen, C. Demeret, S.-V. Werf, A. Fontanet, M. White

EBioMedicine 2021, 70, 103495; doi: 10.1016/j.ebiom.2021.103495.

(P2021-19) Comparison of nasopharyngeal and saliva swabs for the detection of RNA SARS-CoV-2 during mass screening (SALICOV study)

S. Castelain, C. François, B. Demey, A. Aubry, J.-P. Lanoix, G. Duverlie, J.-L. Schmit, E. Brochot

New Microbiol. 2021, 44(1), 59-61.

(P2021-20) Covid-19 serology in nursing home and long-term care: prevalence of seroconversion in the Amiens-Picardie University Hospital

J. Moyet, C. Joseph, E. Brochet, I. Defouillois, T. Brasseur, C. Smarandache, S. Boutalha, S. Castelain, J.-L. Schmit, F. Bloch

Geriatr. Psychol. Neuropsychiatr. Vieil. 2021, 19(3), 274-278; doi: 10.1684/pnv.2021.0952.

(P2021-21) From upper respiratory symptoms to hemophagocytic lymphohistiocytosis: case report of a human adenovirus infection in haploidentical hematopoietic stem cell transplant recipient

B. Demey, C. Brault, J. Maizel, C. Francois

Pathogens 2021, 10(3), 340; doi: 10.3390/pathogens10030340.

(P2021-22) A negative (1,3)- β -D-glucan result alone is not sufficient to rule out a diagnosis of *Pneumocystis pneumonia* in patients with hematological malignancies

C. Damiani, B. Demey, C. Pauc, Y. Le Govic, A. Totet

Front. Microbiol. 2021, 12, Article 713265; doi: 10.3389/fmicb.2021.713265.

(P2021-23) A review of current and promising nontuberculous mycobacteria antibiotics

C. Cantelli, A. Dassonville-Klimpt, P. Sonnet

Future Med. Chem. 2021, 13(16), 1367-1395; doi: 10.4155/fmc-2021-0048.

(P2021-24) The importance of lung hyperperfusion patterns in COVID-19-related AVDS

V. Jounieaux, Y. Mahjoub, I. El-Esper, D.-O. Rodenstein

Eur. J. Nucl. Med. Mol. Imaging 2021, 48(10), 3022-3023; doi: 10.1007/s00259-021-05451-8.

(P2021-25) The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization

Y. Mahjoub, D.-O. Rodenstein, V. Jounieaux

Eur. J. Heart Fail. 2021, 23(3), 493; doi: 10.1002/ejhf.2089.

(P2021-26) Correction to: Hypoxemia and prone position in mechanically ventilated COVID-19 patients: a prospective cohort study

O. Abou-Arab, G. Haye, C. Beyls, P. Huette, P.-A. Roger, M. Guilbart, M. Bernasinski, P. Besserve, F. Trojette, H. Dupont, V. Jounieaux, Y. Mahjoub

Can. J. Anaesth. 2021, 68(8), 1307; doi: 10.1007/s12630-020-01863-6.

(P2021-27) Microvascular flow alterations in critically ill COVID-19 patients: A prospective study

O. Abou-Arab, C. Beyls, A. Khalipha, M. Guilbart, P. Huette, S. Malaquin, B. Lecat, P.-Y. Macq, P.-A. Roger, G. Haye, M. Bernasinski, P. Besserve, S. Soriot-Thomas, V. Jounieaux, H. Dupont, Y. Mahjoub

PLoS One 2021, 16(2), e0246636; doi: 10.1371/journal.pone.0246636.

(P2021-28) Almitrine for COVID-19 critically ill patients - a vascular therapy for a pulmonary vascular disease: Three case reports

P. Huette, O. Abou Arab, V. Jounieaux, M. Guilbart, M. Belhout, G. Haye, H. Dupont, C. Beyls, Y. Mahjoub.

World J. Clin. Cases 2021, 9(14), 3385-3393; doi: 10.12998/wjcc.v9.i14.3385.

(P2021-29) Holistic medicine must mean whole: How to deal with spirituality

J.-P. Lanoix, L. Toussaint

Adv. Mind Body Med. 2021, 35(1), 9-15.

(P2021-30) Repurposing anticancer drugs to tackle malaria

Y. Le Govic, S. Houzé, N. Papon

ChemMedChem 2021, 16(14), 2192-2194; doi: 10.1002/cmdc.202100176.

(P2021-31) Antibiotic therapy of plague: A review

F. Sebbane, N. Lemaître

Biomolécules 2021, 11(5), 724; doi: 10.3390/biom11050724.

(P2021-32) Antimicrobial bombinin-like peptide 3 selectively recognizes and inserts into bacterial biomimetic bilayers in multiple steps

T. Annaïval, F. Ramos-Martín, C. Herrera-León, M. Adélaïde, V. Antonietti, S. Buchoux, P. Sonnet, C. Sarazin, N. D'Amelio

J. Med. Chem. 2021, 64(8), 5185-5197; doi: 10.1021/acs.jmedchem.1c00310.

(P2021-33) Efflux pump overexpression profiling in *Acinetobacter baumannii* and study of new 1-(1-naphthylmethyl)-piperazine analogs as potential efflux inhibitors

M. Choquet, E. Lohou, E. Pair, P. Sonnet, C. Mullié

Antimicrob. Agents Chemother. 2021, 65(9), e0071021; doi: 10.1128/AAC.00710-21.

(P2021-34) Brass alloys: Copper-bottomed solutions against hospital-acquired infections?

E. Dauvergne, C. Mullié

Antibiotics 2021, 10(3), 286; doi: 10.3390/antibiotics10030286.

(P2021-35) Low-valent calix[4]arene glycoconjugates based on hydroxamic acid bearing linkers as potent inhibitors in a model of Ebola virus cis-infection and HCMV-gB-recombinant glycoprotein interaction with MDDC cells by blocking DC-SIGN

K. Chakroun, M. Taouai, V. Porkolab, J. Luczkowiak, R. Sommer, C. Cheneau, D. Mathiron, M.-A. Ben Maaouia, S. Pilard, R. Abidi, C. Mullié, F. Fieschi, P.-J. Cragg, F. Halary, R. Delgado, M. Benazza

J. Med. Chem. 2021, 64(69), 14332-14343; doi: 10.1021/acs.jmedchem.1c00818.

(P2021-36) Minimally invasive fully ROBOT-assisted cochlear implantation in humans: Preliminary results in five consecutive patients

N. Klopp-Dutote, M. Lefranc, V. Strunski, C. Page

Clin. Otolaryngol. 2021, 46,1326-1330; doi: 10.1111/coa.13840.

(P2021-37) Streptogramins for the treatment of infections caused by Gram-positive pathogens

S. Reissier, V. Cattoir

Expert Rev. Anti-infect. Ther. 2021, 19(5), 587-599; doi: 10.1080/14787210.2021.1834851.

(P2021-38) Distinct expression profiles of regulatory RNAs in the response to biocides in *Staphylococcus aureus* and *Enterococcus faecium*

L. Dejoies, K. Le Neindre, S. Reissier, B. Felden, V. Cattoir

Sci. Rep. 2021, 11(1), 6892; doi: 10.1038/s41598-021-86376-y.

(P2021-39) It is still PCP that can stand for *Pneumocystis pneumonia*: Appeal for generalized use of only one acronym

G. Nevez, A. Totet, O. Matos, E.-J. Calderon, R.-F. Miller, S. Le Gal
Med. Mycol. 2021, 59(8), 842-844; doi: 10.1093/mmy/myab024.

(P2021-40) Association between renin-angiotensin system inhibitors and COVID-19 complications
S. Liabeuf, J. Moragny, Y. Bennis, B. Batteux, E. Brochot, J.-L. Schmit, J.-P. Lanoix, C. Andrejak, O. Ganry, M. Slama, J. Maizel, Y. Mahjoub, K. Masmoudi, V. Gras-Champel
Eur. Heart J. - Cardiovascular Pharmacother. 2021, 7(5), 426-434; doi.org/10.1093/ehjcvp/pvaa062.

(P2021-41) Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial

V. Dubée, P.-M. Roy, B. Vielle, E. Parot-Schinkel, O. Blanchet, A. Darsonval, C. Lefeuvre, C. Abbara, S. Boucher, E. Devaud, O. Robineau, P. Rispal, T. Guimard, E. d'Anglejean, S. Diamantis, M.-A. Custaud, I. Pellier, A. Mercat, A. Brangier, P. Codron, J.-M. Lemée, V. Pichon, R. Dhersin, G. Urbanski, C. Lavigne, R. Courtois, H. Danielou, J. Lebreton, R. Vatan, N. Crochette, J.-B. Lainé, L. Perez, S. Blanchi, H. Hitoto, L. Bernard, F. Maillot, S. Marchand Adam, J.-P. Talarmin, E. Gaigneux, P. Motte-Vincent, M. Morrier, D. Merrien, Y. Bleher, M. Flori, A. Ducet-Boiffard, O. Colin, R. Février, P. Thill, M. Tetart, F. Demaeght, B. Lafond-Desmurs, M. Pradier, A. Meybeck, M. Picaud, T. Prazuck, G. Chapelet, A. Rouaud, P. Le Turnier, S. Sunder, A. Lorleac'h, C. Dollon, A. Jacquet, F. Le Vely, P. Gazeau, S. Ansart, H. Roger, F. Laterza, R. Buzelé, F. Tahmi, R. Lepeule, K. Lacombe, B. Lefebvre, T. Célarier, A. Gagneux-Brunon, E. Botelho-Nevers, M. Bernard, C. Garnier, M. Mourguet, G. Pugnet, S. Vienne-Noyes, G. Martin-Blondel, P. Delobel, G. Grouteau, A. Debard, L. Guilleminault, P. Arias, C. Chakvetadze, C. Flateau, A. Kopp, A. Putot, J. Barben, S. Mouries-Martin, V. Nuss, L. Piroth, Y.-E. Claessens, V. Hentgen, M. Martinot, M. Bach-Bunner, T. Bonijoly, S. Gravier, J.-M. Michel, M. Andreu, M. Roriz, A. Baldolli, J. Brochard, O. Grossi, S. Pineau, J. Brisset, E. Desvaux, G. Gondran, J.-F. Faucher, P.-A. Quesnel, H. Bezanahary, C. Danthu, B. Gutierrez, K. Ly, Y. Simonneau, A. Cypierre, P. Pinet, H. Durox, S. Ducroix-Roubertou, C. Genet, G. Beraud, G. Le Moal, B. Rammaert, J.-P. Lanoix, C. Andrejak, C. Joseph, S. Soriot-Thomas, R. Dhote, S. Abad, R. Benainous, J.-F. Boitiaux, G. Briend, C. Gonfroy, S. Harent, A. Lagrange, A. Tone, L. Wayenberg, S. Desoutter, N. Ettahar, T. Gey, V. Leroy, S. Gaillard, A. Toma, A. Broussier, S. Etienne, Y. Spivac, B. Martha, N. Roch, P. Diaz, D. N'guyen Baranoff, S. Rebaudet, F. Jourda, V. Zeller, B. Bienvenu, A. Boyer, I. Pellier, A. Mercat, A. Darsonval, O. Blanchet, M.-A. Custaud, C. Lefeuvre, E. Parot-Schinkel, B. Vielle, M. Briet, P.-M. Roy, V. Dubée, B. Guidet, P. Mismetti, E. Vicaut, O. Sanchez, P. Girard, A. Elias, F. Couturaud, B. Gable, S. Lazareff, L. Carballido, C. Hue, J.-M. Chrétien, A. Goraguer, L. van Eeckhoutte
Clin. Microbiol. Infect., 2021, 27(8), 1124-1130; doi.org/10.1016/j.cmi.2021.03.005.

(P2021-42) Which features of an outpatient treatment for COVID-19 would be most important for pandemic control? A modelling study

J.-P. Lanoix, Y. Mammeri, J.-L. Schmit, M. Lefranc

J. R. Soc. Interface 2021, 18, 20210319; doi.org/10.1098/rsif.2021.0319.

(P2021-43) Cyclodextrin complexation as a way of increasing the aqueous solubility and stability of carvedilol

S. Rigaud, D. Mathiron, T. Moufawad, D. Landy, F. Djedaini-Pilard, F. Marçon

Pharmaceutics 2021, 13(11), 1746; doi.org/10.3390/pharmaceutics13111746.

(P2021-44) Neutralizing antibodies directed against SARS-CoV-2 in a population residing in a nursing home and a long-term care unit

J. Moyet, F. Helle, G. Bourdenet, C. Joseph, B. Gubler, E. Brochot, F. Bloch

Geriatr. Gerontol. Int. 2021, 21(11), 1066-1068; doi.org/10.1111/ggi.14289.

(P2021-45) The impact of pre-graft serology on the risk of BKPyV infection post-renal transplantation

F. Dakroub, A. Touzé, F.-A. Sater, T. Fiore, V. Morel, C. Tinez, F. Helle, C. François, G. Choukroun, C. Presne, N. Guillaume, G. Duverlie, S. Castelain, H. Akl, E. Brochot

Nephrol. Dial. Transplant. 2021, gfab279; doi.org/10.1093/ndt/gfab279.

(P2021-46) Prospective multicenter validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced NSCLC

M. Ilié, J. Mazières, E. Chamorey, S. Heeke, J. Benzaquen, B. Thamphya, J. Boutros, A. Tiotiu, J. Fayada, J. Cadranel, M. Poudenx, D. Moro-Sibilot, F. Barlesi, J. Thariat, C. Clément-Duchêne, P. Tomasin, V. Hofman, C.-H. Marquette, P. Hofman; STALKLUNG01 Study Consortium Investigators, collaborator V. Jounieaux

J. Thorac. Oncol. 2021, 16(5), 807-816; doi: 10.1016/j.jtho.2021.01.1617.

(P2021-47) Impact of rifampicin dose in bone and joint prosthetic device infections due to *Staphylococcus spp.*: A retrospective single-center study in France

M. Tonnelier, A. Bouras, C. Joseph, Y. E. Samad, B. Brunschweiler, J.-L. Schmit, C. Mabile, J.-P. Lanoix

BMC Infect. Dis. 2021, 21, 174; doi.org/10.1186/s12879-021-05832-2.

(P2021-48) Antimicrobial preservation efficacy of liquid glucose and liquid maltitol syrups with and without 0.1% sorbic acid

T. Carpentier, E. Maillard, M. Royer, L. Mustapha, F. Marçon

Pharm. Technol. Hosp. Pharm., 2021, 6(1), 20210007; doi.org/10.1515/pthp-2021-0007.

(P2021-49) Antimicrobial peptide K11 selectively recognises bacterial biomimetic membranes and acts by twisting their bilayers

F. Ramos-Martín, C. Herrera-León, V. Antonietti, P. Sonnet, C. Sarazin, N. D'Amelio

Pharmaceutics 2021, 14(1), 1-22; doi: 10.3390/ph14010001.

(P2021-50) Oral acute toxicity, influence on the gastrointestinal microbiota and *in vivo* anti-salmonellosis effect of *Zizyphus lotus* (L.) and *Ruta chalepensis* (L.) essential oils

N. El H. Bekkar, B. Meddah, B. Keskin, P. Sonnet

J. Appl. Biotechnol. Rep. 2021, 8(1), 13-26; doi: 10.30491/JABR.2020.229267.1217.

(P2021-51) Crystal structure of 1-(3-ferrocenyl-2-methylpyrrolo[1,2-a]quinoxalin-4-yl)piperazine hydrochloride

J. Guillon, N. Pinaud, S. Savrimoutou, M. Marchivie, S. Moreau, S. Albenque-Rubio, P. Sonnet
X-Ray Structure Analysis Online 2021, 37, 65-67; doi: 10.2116/xraystruct.37.65.

(P2021-52) A novel multi-target strategy to attenuate the progression of Parkinson's disease with diamine hybrid AGE/ALE inhibitor

N. A. Sasaki, P. Sonnet

Future Med. Chem. 2021, 13(24), 2185-2200; doi.org/10.4155/fmc-2021-0217.

(P2021-53) Quorum sensing inhibitors to quench *P. aeruginosa* pathogenicity

M. Duplantier, E. Lohou, P. Sonnet

Pharmaceuticals 2021, 14, 1262; doi:10.3390/ph14121262.

(P2021-54) The regulatory RNA *ern0160* confers a potential selective advantage to *Enterococcus faecium* for intestinal colonization

S. Reissier, K. Le Neindre, V. Bordeau, L. Dejoies, A. Le Bot, B. Felden, V. Cattoir, M. Revest

Front. Microbiol. 2021, 12, 757227; doi: 10.3389/fmicb.2021.757227.

(P2021-55) Nosocomial outbreak of monoclonal VIM carbapenemase-producing *Enterobacter cloacae* complex in an intensive care unit during the COVID-19 pandemic: an integrated approach

C. Mullié, D. Lemonnier, C. C. Adjidé, J. Maizel, G. Mismacque, A. Cappe, T. Carles, M. Pierson-Marchandise, Y. Zerbib

J. Hosp. Infect. 2021, 120, 48-56; doi: 10.1016/j.jhin.2021.11.017.

(P2021-56) Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Q. Le Hingrat, B. Visseaux, C. Laouenan, S. Tubiana, L. Bouadma, Y. Yazdanpanah, X. Duval, C. Burdet, H. Ichou, F. Damond, M. Bertine, N. Benmalek, C. Choquet, J.-F. Timsit, J. Ghosn, C. Charpentier, D. Descamps, N. Houhou-Fidouh; the French COVID cohort management committee, and the CoV-CONTACT study group, member C. Andréjak

Clin. Microbiol. Infect. 2021, 27(11), 1713; doi: 10.1016/j.cmi.2021.09.034.

(P2021-57) Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review

N. Gault, M. Esposito-Farèse, M. Revest, J. Inamo, A. Cabié, É. Polard, J.-S. Hulot, J. Ghosn, C. Chirouze, L. Deconinck, J.-L. Diehl, J. Poissy, O. Epaulard, B. Lefèvre, L. Piroth, E. De Montmollin, E. Oziol, M. Etienne, C. Laouenan, P. Rossignol, D. Costagliola, E. Vidal-Petiot; the French-Covid cohort investigators and study group, member C. Andréjak

Fundam. Clin. Pharmacol. 2021, 35(6), 1141-1158; doi.org/10.1111/fcp.12683.

(P2021-58) Sera neutralizing activities against severe acute respiratory syndrome coronavirus 2 and multiple variants 6 months after hospitalization for coronavirus disease 2019

M. Betton, M. Livrozet, D. Planas, A. Fayol, B. Monel, B. Védie, T. Bruel, E. Tartour, N. Robillard, J.-C. Manuguerra, A. Blanchard, J. Ghosn, B. Visseaux, H. Péré, D. Lebeaux, O. Schwartz, D. Veyer, J.-S. Hulot; French COVID Cohort Study Group, member [C. Andréjak](#)
Clin. Infect. Dis. 2021, 73(6), e1337-e1344; doi.org/10.1093/cid/ciab308.

(P2021-59) Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients

Y. Yazdanpanah, French COVID cohort investigators and study group, member [C. Andréjak](#)
J. Med. Virol. 2021, 93(4), 2149-2159; doi.org/10.1002/jmv.26601.

(P2021-60) Cardiac performance in patients hospitalized with COVID-19: A 6 month follow-up study

A. Fayol, M. Livrozet, P. Boutouyrie, H. Khettab, M. Betton, V. Tea, A. Blanchard, R.-M. Bruno, J.-S. Hulot; French COVID cohort study group, member [C. Andréjak](#)
ESC Heart Failure 2021, 8, 2232-2239; doi: 10.1002/ehf2.13315.

(P2021-61) Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia

M. Ghanem, M. Homps-Legrand, M. Garnier, L. Morer, T. Goletto, J. Frija-Masson, P.-H. Wicky, P. Jaquet, C. Bancal, M. Hurtado-Nedelec, L. de Chaisemartin, M. Jaillet, A. A. Mailleux, C. Quesnel, N. Poté, M.-P. Debray, E. de Montmollin, C. Neukirch, R. Borie, C. Taillé, B. Crestani; the French COVID cohort study group, member [C. Andréjak](#)
Am. J. Physiol. Lung Cell Mol. Physiol. 2021, 321, L847-L858; doi: 10.1152/ajplung.00105.2021.

(P2021-62) Association between psychological distress, cognitive complaints, and neuropsychological status after a severe COVID-19 episode: A cross-sectional study

C. Gouraud, H. Bottemanne, K. Lahlou-Laforêt, A. Blanchard, S. Günther, E. Batti Salma, E. Auclin, F. Limosin, J.-S. Hulot, D. Lebeaux, C. Lemogne; the French COVID study group, member [C. Andréjak](#)
Front. Psychiatry 2021, 12, Article 725861; doi: 10.3389/fpsyt.2021.725861.

(P2021-63) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

P. Bastard, A. Gervais, T. Le Voyer, J. Rosain, Q. Philippot, J. Manry, E. Michailidis, H.-H. Hoffmann, S. Eto, J.-L. Casanova, +190 authors; the French COVID study group, member [C. Andréjak](#)
Sci. Immunol. 2021, 6(62), eabl4340; doi: 10.1126/sciimmunol.abl4340.

(P2021-64) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

T. Asano, B. Boisson, F. Onodi, D. Matuozzo, M. Moncada-Velez, M. R. L. M. Renkilaraj, P. Zhang, L. Meertens, A. Bolze, J.-L. Casanova, +106 authors; the French COVID study group, member [C. Andréjak](#)
Sci. Immunol. 2021, 6(62), eabl4348; doi: 10.1126/sciimmunol.abl4348.

(P2021-65) Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events

M. Bachir, L. Guglielmetti, S. Tunesi, T. Billard-Pomares, S. Chiesi, J. Jaffré, H. Langris, V. Pourcher, F. Schramm, N. Lemaître, J. Robert; Isoniazid Resistance Group
Int. J. Infect. Dis. 2021, 107, 86-91; doi: 10.1016/j.ijid.2021.03.093.

(P2021-66) Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study

P. Bemer, O. Peuchant, H. Guet-Revillet, J. Bador, C. Balavoine, D. Basille, G. Beltramo, F.-X. Blanc, E. Blanchard, S. Boulanger, A. Bourgoïn, D. Boutoille, E. Cambau, F. Canis, D. Caparros, A. Carricajo, C. Carrière, G. Couetdic, F. Couturaud, J.-C. Dalphin, T. Degot, M. Desquiens, G. Devouassoux, J.-M. Duez, O. Dumitrescu, M. Dupuy-Grasset, A. Gaudart, M. Georges, C. Godet, S. Godreuil, A. Guillouzouic, F. Hamdad-Daoudi, G. Héry-Arnaud, C. Koebel, A. Lagrange, P. Lanotte, S. Marchand-Adam, F. Mougari, M. Murriss, I. Patry, M. Pérouse de Montclos, L. Raskine, K. Risso, C. Segonds, D. Sicard, D. Terru, A. Vachée, J.-M. Vergnon, C. Martin, F. Schramm, C. Andrejak
BMC Pulm. Med. 2021, 21(1), 333 ; doi: 10.1186/s12890-021-01701-5.

(P2021-67) Case reports: Bronchial mucosal vasculature is also involved in the acute vascular distress syndrome of COVID-19

V. Jounieaux, D. Basille, B. Toubanc, C. Andrejak, D. O. Rodenstein, Y. Mahjoub
Front. Med. 2021, 8, Article 710992; doi: 10.3389/fmed.2021.710992.

(P2021-68) SARS-COV-2 infection in children and red blood cell distribution width

H. Tchidjou Kuekou, L. Palandri, S. Pouplin, V. LiThiao Te, E. Righi, S. Castelain, J. Ricard
Cureus 2021, 13(9), e17837; doi: 10.7759/cureus.17837.

(P2021-69) Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021

A. Gaymard, P. Bosetti, A. Feri, G. Destras, V. Enouf, A. Andronico, S. Burrel, S. Behillil, C. Sauvage, A. Bal, F. Morfin, S. Van Der Werf, L. Josset; ANRS MIE AC43 COVID-19; French viro COVID group, F. Blanquart, B. Coignard, S. Cauchemez, B. Lina
Euro. Surveill. 2021, 26(9), 2100133; doi: 10.2807/1560-7917.ES.2021.26.9.2100133.

(P2021-70) Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group

S. Rocchi, E. Scherer, C. Mengoli, A. Alanio, F. Botterel, M.-E. Bougnoux, S. Bretagne, M. Cogliati, M. Cornu, F. Dalle, C. Damiani, J. Denis, S. Fuchs, M. Gits-Muselli, F. Hagen, C. Halliday, R. Hare, X. Iriart, C. Klaassen, M. Lackner, M. Lengerova, V. Letscher-Bru, F. Morio, C. Nourrisson, W. Posch, B. Sendid, J. Springer, B. Willinger, P.-L. White, R.-A. Barnes, M. Cruciani, J.-P. Donnelly, J. Loeffler, L. Millon
Med. Mycol. 2021, 59(2), 126-138; doi: 10.1093/mmy/myaa036.

(P2021-71) Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

N. Veziris, C. Andréjak, S. Bouée, C. Emery, M. Obradovic, R. Chiron
BMC Infect. Dis. 2021, 21(1), 1165; doi: 10.1186/s12879-021-06825-x.

III) Publications nationales

(N2021-01) BioQuiz : Parasitologie « Une histoire d'éperon »

C. Saint, C. Damiani, J. Boissier, A. Totet, Y. Le Govic

Revue Francophone des Laboratoires 2021, N°531, 71-73; doi: 10.1016/S1773-035X(21)00111-8.

(N2021-02) BioQuiz : Parasitologie « Oh les jolis veaux ! »

J. Crestia, C. Damiani, D. Costa, A. Totet, Y. Le Govic

Revue Francophone des Laboratoires 2021, N°533, 79-80; doi: 10.1016/S1773-035X(21)00174-X.

(N2021-03) Les virus : des dompteurs de vésicules

L. Handala, F. Helle

Virologie 2021, 25(6), 317-323; doi: 10.1684/vir.2021.0923.

IV) Pré-publications

(pP2021-1) Antiviral drugs in hospitalized patients with COVID-19 – the DisCoVeRy trial

F. Ader, N. Peiffer-Smadja, J. Poissy, M. Bouscambert-Duchamp, D. Belhadi, A. Diallo, C. Delmas, J. Saillard, A. Dechanet, N. Mercier, A. Dupont, T. Alfaiate, F.-X. Lescure, F. Raffi, F. Goehringer, A. Kimmoun, S. Jaureguiberry, J. Reignier, S. Nseir, F. Danion, R. Clere-Jehl, K. Bouiller, J. Navellou, V. Tolsma, A. Cabie, C. Dubost, J. Courjon, S. Leroy, J. Mootien, R. Gaci, B. Mourvillier, E. Faure, V. Pourcher, S. Gallien, O. Launay, K. Lacombe, J.-P. Lanoix, A. Makinson, G. Martin-Blondel, L. Bouadma, E. Botelho-Nevers, A. Gagneux-Brunon, O. Epaulard, L. Piroth, F. Wallet, J.-C. Richard, J. Reuter, T. Staub, M. Hites, M. Noret, C. Andréjak, G. Peytavin, B. Lina, D. Costagliola, Y. Yazdanpanah, C. Burdet, France Mentre

MedRxiv 2021; doi.org/10.1101/2021.01.08.20248149.

(pP2021-2) Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

N. Veziris, C. Andréjak, S. Bouée, C. Emery, M. Obradovic, R. Chiron

Res. Sq. 2021; doi :10.21203/rs.3.rs-668178/v1.

(pP2021-3) Remdesivir for the treatment of hospitalised patients with COVID-19 (DisCoVeRy): A randomised, controlled, open-label trial

F. Ader, M. Bouscambert-Duchamp, M. Hites, N. Peiffer-Smadja, J. Poissy, D. Belhadi, A. Diallo, C. Delmas, J. Saillard, A. Dechanet, C. Fougerou, M. Lê, G. Peytavin, N. Mercier, P. Velou, S. Tubiana, X. Lescure, E. Faure, S. Nseir, J. Richard, F. Wallet, F. Goehringer, B. Lefèvre, A. Kimmoun, F. Raffi, B. Gaborit, J. Reignier, J.-P. Lanoix, C. Andréjak, Y. Zerbib, F. Bani-Sadr, B. Mourvilliers, F. Danion, Y. Ruch, R. Clere-Jehl, V.-L. Moing, K. Klouche, K. Lacombe, G. Martin-Blondel, F. Vardon-Bouines, A. Cabié, J. Turmel, L. Piroth, M. Blot, E. Botelho-Nevers, A. Gagneux-Brunon, G. Thiery, F. Bénézit, R. Gaci, J. Mootien, S. Gallien, D. Garot, K. Bouiller, L. Epelboin, S. Jauréguiberry, A. Gaynard, G. Verschelden, S. Braz, J.-F. Ribeiro, M. Joannidis, T. Staub, A. Altdorfer, R. Greil, A. Egle, J. Guedj, M. Noret, Jr RR, J. Paiva, B. Lina, D. Costagliola, Y. Yazdanpanah, C. Burdet, F. Mentre

Preprints with The Lancet 2021; doi: 10.2139/ssrn.3854628 PPR: PPR360916.

IV) Contributions à des ouvrages

(C2021-01) Asthme ou BPCO ? : peut-on toujours faire la différence ? Quelle conséquence pratique pour la prise en charge ?

M. Drucbert, C. Andréjak

Revue Preuves & Pratiques 2021.

V) Communications orales

(O2021-01) Évaluation des risques psychosociaux en unité de production

S. Cadoret, V. Ratte, C. Delaire, F. Marçon

24^e Journées Européennes du GERPAC, Hyères, 6-8 Octobre 2021.

(O2021-02) Optimisation de l'utilisation du picomix® pour le mélange des poudres d'amiodarone et de lactose

D. Alloh Nammou, E. Lefebvre, E. Kansou, M. Royer, L. Mustapha, F. Marçon

24^e Journées Européennes du GERPAC, Hyères, 6-8 Octobre 2021.

(O2021-03) La révolution des vaccins à ARN messenger

F. Helle (*conférencier invité*)

Journée de formation des pharmaciens sur « La virologie », Amiens, 2021.

(O2021-04) New 2-heteroaryl-4-quinolones as potential multi-drug resistant ESKAPEE anti-virulence agents

M. Duplantier, E. Lohou, P. Sonnet

28th Young Research Fellows Meeting of French Medicinal Chemistry Society, Paris, February 11-12, 2021 (*flash presentation*).

(O2021-05) Novel enantiopure arylaminoalcohols as promising antimalarial drugs to struggle resistant *P. falciparum*

C. Tisnerat, A. Dassonville-Klimpt, P. Sonnet

ACS Fall 2021 National Meeting & Exposition, Atlanta, USA, August 22-26, 2021 (*webinaire*); doi.org/10.1021/scimeetings.1c01205.

(O2021-06) Design and study of potential FabZ inhibitors as antimicrobial drugs

L. Bibens, J.-P. Becker, N. Lemaitre, C. Damiani, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

29th Annual GP2A Medicinal Chemistry Conference, August 25-27, 2021 (*webinaire*).

(O2021-07) Synthesis and antipseudomonal activities of new iron chelator-ciprofloxacin conjugates

P. Loupias, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

29th Annual GP2A Medicinal Chemistry Conference, August 25-27, 2021 (*webinaire*); **Prix de la meilleure communication orale (étudiante post-doctorante)**.

(O2021-08) Nouvelles approches thérapeutiques en infectiologie

P. Sonnet (*conférencier invité*)

5^e Journée amiénoise de l'infectiologie, Amiens, 19 Mars 2021.

(O2021-09) Les micro-ARNs du Polyomavirus BK : cinétique et intérêt diagnostique chez les patients transplantés de rein

B. Demey, V. Descamps, C. Presne, F. Helle, C. François, G. Duverlie, S. Castelain, E. Brochot
13^e Journée de l'AFIPP, 30 Septembre-1^{er} Octobre 2021 (conférence virtuelle).

(O2021-10) Le quorum sensing au cœur d'une nouvelle stratégie thérapeutique pour contrer l'antibiorésistance

M. Duplantier, E. Lohou, P. Sonnet

5^e Journée amiénoise de l'infectiologie, Amiens, 19 Mars 2021 (présentation flash).

(O2021-11) Caractérisation moléculaire des systèmes d'efflux chez *Acinetobacter baumannii*. Synthèse et évaluation de nouveaux inhibiteurs analogues de la 1-(1-naphtylméthyl)-pipérazine

M. Choquet, E. Lohou, E. Pair, C. Mullié, P. Sonnet

5^e Journée amiénoise de l'infectiologie, Amiens, 19 Mars 2021 (présentation flash).

(O2021-12) Etude d'analogues de sidérophores comme vecteurs d'antibiotiques

P. Loupias, A. Dassonville-Klimpt, P. Sonnet

5^e Journée amiénoise de l'infectiologie, Amiens, 19 Mars 2021 (présentation flash).

(O2021-13) Novel NTM treatments and approaches, repurposed to bacteriophages

C. Andréjak

European Respiratory Society (ERS) International Congress, September 5-8, 2021 (webinaire).

(O2021-14) Management of COVID-19: where are we ?

C. Andréjak

European Respiratory Society (ERS) International Congress, September 5-8, 2021 (webinaire).

(O2021-15) Guidelines on Nontuberculous mycobacterial pulmonary disease (expert session)

C. Andréjak

31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), July 9-12, 2021 (webinaire).

(O2021-16) Tuberculose et mycobactérioses

C. Andréjak

22^e Journées Nationales d'Infectiologie, Montpellier, 30 Août-1^{er} Septembre 2021.

(O2021-17) Prise en charge de la pneumonie à SARS-CoV-2

C. Andréjak

22^e Journées Nationales d'Infectiologie, Montpellier, 30 Août-1^{er} Septembre 2021.

(O2021-18) Pneumonies virales épidémiques : Quelle stratégie pour la prise en charge ?

C. Andréjak

25^e Congrès de Pneumologie de Langue Française (CPLF), 29 Janvier 2021 (webinaire).

(O2021-19) Mycobactéries non tuberculeuses: Nouveautés thérapeutiques présentes et futures

C. Andréjak

25^e Congrès de Pneumologie de Langue Française (CPLF), 29 Janvier 2021 (webinaire).

(O2021-20) Actualités Covid-19

C. Andréjak

25^e Congrès de Pneumologie de Langue Française (CPLF), 29 Janvier 2021 (webinaire).

VI) Communications affichées

(A2021-01) Synthesis and study of gallium complexes as potential antipseudomonal agents

P. Loupias, I. Dechamps-Olivier, L. Dupont, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

7th International Electronic Conference on Medicinal Chemistry, chaired by Dr. Jean Jacques Vanden Eynde, MDPI AG, Sciforum Electronic Conference Series, November 1-30, 2021; doi.org/10.3390/ECMC2021-11410 (electronic presentation).

(A2021-02) Novel antimalarial enantiopure arylaminoalcohols as efflux pump substrates to fight resistant *P. falciparum*

C. Tisnerat, J. Schneider, C. Damiani, P. Agnamey, C. Mullié, A. Totet, E. Sevin, A. Dassonville-Klimpt, F. Gosselet, P. Sonnet

7th International Electronic Conference on Medicinal Chemistry, chaired by Dr. Jean Jacques Vanden Eynde, MDPI AG, Sciforum Electronic Conference Series, November 1-30, 2021; doi.org/10.3390/ECMC2021-11407 (electronic presentation).

(A2021-03) Design, synthesis and antimicrobial activities of potential FabZ inhibitors

L. Bibens, J.-P. Becker, N. Lemaitre, C. Damiani, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

7th International Electronic Conference on Medicinal Chemistry, chaired by Dr. Jean Jacques Vanden Eynde, MDPI AG, Sciforum Electronic Conference Series, November 1-30, 2021; doi.org/10.3390/ECMC2021-11408 (electronic presentation).

(A2021-04) Serum (1,3)- β -D-glucan cannot reliably exclude *Pneumocystis pneumonia* in patients with hematological malignancies

Y. Le Govic, B. Demey, C. Pauc, C. Damiani, A. Totet

10th Trends In Medical Mycology (TIMM), Aberdeen, Ecosse, October 8-11, 2021.

(A2021-05) Pancytopenia due to flucytosine overdose in a critically ill patient under continuous venovenous hemofiltration

A. Cappe, Y. Le Govic, P.-Y. Macq, Y. Bennis, L. Villeret, A. Mary

Congrès SFP/SFMM, Lyon, 28-29 Octobre 2021.

(A2021-06) Antibacterial activity of brass post-cleaning/desinfection treatments

E. Dauvergne, D. Declerck, C. Lacquemant, C. Mullié

6th International Conference on Prevention & Infection Control, Genève, Suisse, September 14-17, 2021.

(A2021-07) Efficacité de la conservation antimicrobienne des sirops de glucose et de maltitol avec et sans conservateur pour les préparations pédiatriques

T. Carpentier, E. Maillard, M. Royer, L. Mustapha, F. Marçon

24^e Journées Européennes du GERPAC, Hyères, 6-8 Octobre 2021.

(A2021-08) Les micro-ARNs du Polyomavirus BK : cinétique et intérêt diagnostique chez les patients transplantés de rein

B. Demey, V. Descamps, C. Presne, F. Helle, C. François, G. Duverlie, S. Castelain, E. Brochot

XXIII^e Journées Francophones de Virologie, Montpellier, 26-27 Avril 2021.

(A2021-09) New 2-heteroaryl-4-quinolones as potential multi-drug resistant ESKAPEE anti-virulence agents

M. Duplantier, E. Lohou, P. Sonnet

28th Young Research Fellows Meeting of French Medicinal Chemistry Society, Paris, February 11-12, 2021.

(A2021-10) Synthesis and study of gallium piperazine-based complexes as potential antipseudomonal agents

P. Loupias, I. Dechamps-Olivier, L. Dupont, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

28th Young Research Fellows Meeting of French Medicinal Chemistry Society, Paris, February 11-12, 2021.

(A2021-11) Novel arylaminoalcohol-based compounds: promising antimalarial drugs

C. Tisnerat, J. Schneider, C. Damiani, P. Agnamey, C. Mullié, A. Totet, A. Dassonville-Klimpt, P. Sonnet

28th Young Research Fellows Meeting of French Medicinal Chemistry Society, Paris, February 11-12, 2021.

(A2021-12) Design of FabZ inhibitors as potential antibiotics

L. Bibens, J.-P. Becker, N. Lemaître, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

28th Young Research Fellows Meeting of French Medicinal Chemistry Society, Paris, February 11-12, 2021.

(A2021-13) Anti-virulence 2-heteroaryl-4-quinolone agents to tackle multi-drug resistant *Pseudomonas aeruginosa* bacteria

M. Duplantier, E. Lohou, P. Sonnet

ACS Fall 2021 National Meeting & Exposition, Atlanta, USA, August 22-26, 2021 (*webinaire*); doi.org/10.1021/scimeetings.1c01067.

(A2021-14) Efflux pump overexpression profiling in *Acinetobacter baumannii* and study of new 1-(1-NaphthylMethyl)-Piperazine analogs as potential inhibitors

M. Choquet, M. Duplantier, E. Lohou, E. Pair, C. Mullié, P. Sonnet

ACS Fall 2021 National Meeting & Exposition, Atlanta, USA, August 22-26, 2021 (*webinaire*); doi.org/10.1021/scimeetings.1c01071.

(A2021-15) Design and study of new potential FabZ inhibitors as promising antimicrobial drugs

L. Bibens, J.-P. Becker, N. Lemaître, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

ACS Fall 2021 National Meeting & Exposition, Atlanta, USA, August 22-26, 2021 (*webinaire*).

(A2021-16) A Trojan Horse strategy: synthesis and antipseudomonal activities of new iron chelator-ciprofloxacin conjugates

P. Loupias, L. Bibens, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

ACS Fall 2021 National Meeting & Exposition, Atlanta, USA, August 22-26, 2021 (*webinaire*).

(A2021-17) Asymmetric synthesis of novel arylaminoalcohol-based compounds as promising antimalarial drugs

C. Tisnerat, J. Schneider, C. Damiani, P. Agnamey, C. Mullié, A. Totet, A. Dassonville-Klimpt, F. Gosselet, P. Sonnet

21st Tetrahedron Symposium, June 21-24, 2021 (*webinaire*).

(A2021-18) New 2-heteroaryl-4-quinolones as potential anti-virulence agents to tackle multi-drug resistant *Pseudomonas aeruginosa* bacteria

M. Duplantier, E. Lohou, P. Sonnet

21st Tetrahedron Symposium, June 21-24, 2021 (*webinaire*).

(A2021-19) Design and study of potential FabZ inhibitors as antimicrobial drugs

L. Bibens, J.-P. Becker, N. Lemaitre, C. Damiani, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

29th Annual GP2A Medicinal Chemistry Conference, August 25-27, 2021 (*webinaire*).

(A2021-20) Synthesis and antipseudomonal activities of new iron chelator-ciprofloxacin conjugates

P. Loupias, N. Taudon, A. Dassonville-Klimpt, P. Sonnet

29th Annual GP2A Medicinal Chemistry Conference, August 25-27, 2021 (*webinaire*).

(A2021-21) Le potentiel des peptides antimicrobiens dans la lutte contre la résistance microbienne

F. Ramos-Martín, C. Herrera-León, T. Annaïval, M. Adélaïde, V. Antonietti, S. Buchoux, P. Sonnet, C. Sarazin, N D'Amelio

9^e Journées Condorcet, 1-2 Juillet 2021 (*webinaire*).

(A2021-22) Application de la métabolomique non ciblée pour l'étude de l'activité anti-biofilm de nouvelles molécules sur *Pseudomonas aeruginosa*

C. Dalle, M. Duplantier, E. Lohou, L. Desnouveaux, P. Sonnet, N. Taudon

14^e Journées Scientifiques du RFMF (Réseau Francophone Métabolomique et Fluxomique), Aussois, 23-26 Novembre 2021.

VII) Séminaires de laboratoire

(S2021-01) Métabolisme du fer chez *Scedosporium apiospermum*, un pathogène fongique émergent dans la mucoviscidose

Yohann LE GOVIC

CURS, UPJV, 21 Janvier 2021.

(S2021-02) *In vitro* evaluation of antimicrobial efficacy and durability of three copper surfaces used in healthcare

Emilie DAUVERGNE

UFR de Pharmacie, UPJV, 4 Février 2021.

(S2021-03) Vésicules Extracellulaires et néphropathies à Virus BK chez les transplantés rénaux

Marine BENTZ

CURS, UPJV, 25 Février 2021.

(S2021-04) Recent advances in antimalarial drug development: focus on novel targets

Camille TISNERAT

UFR de Pharmacie, UPJV, 11 Mars 2021.

(S2021-05) Présentation de son parcours et de son sujet de thèse

Sébastien RIGAUD

CURS, UPJV, 25 Mars 2021.

(S2021-06) Présentation de son parcours et de son sujet de thèse

Sophie REISSIER

CURS, UPJV, 8 Avril 2021.

(S2021-07) Etude du mécanisme d'action d'arylaminoalcools antipaludiques

Floriane SOLERS

CURS, UPJV, 22 Avril 2021.

(S2021-08) Les micro-ARNs du polyomavirus BK : cynetique et intérêt clinique chez les patients transplantés du rein

Baptiste DEMEY

UFR de Pharmacie, UPJV, 20 Mai 2021.

(S2021-09) Conséquences des mutations de FabZ sur le fitness de *Yersinia pestis*

Alix LAFITTE

CURS, UPJV, 3 Juin 2021.

(S2021-10) Caractérisation moléculaire des systèmes d'efflux chez *Acinetobacter baumannii* et étude de nouveaux inhibiteurs analogues de la 1-(1-naphtylméthyl)-pipérazine

Morgane Choquet

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-11) Synthèse et étude de conjugués sidérophore-ciprofloxacine pour lutter contre *Pseudomonas aeruginosa*

Pauline LOUPIAS

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-12) Synthèse et étude d'inhibiteurs potentiels de FabZ

Laurie BIBENS

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-13) Activité antibactérienne du lait AB+® après traitement de nettoyage/désinfection

Emilie DAUVERGNE

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-14) Présentation de la FHU

Claire ANDRÉJACK

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-15) Evaluation de l'activité de composés analogues de la méfloquine contre diverses mycobactéries non-tuberculeuses

Francois PELTIER

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-16) Etude moléculaire des voies de détoxification de l'hème par *Plasmodium falciparum*

Yohann LE GOVIC

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-17) Etude des interactions entre transporteurs ABC et les arylaminoalcools antipaludiques

Camille TISNERAT

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-18) Caractérisation des formes enveloppées du virus BK (eBKPyV)

Marine BENTZ

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-19) Les micro-ARNs du Polyomavirus BK : Cinétiques et intérêt diagnostique chez les patients transplantés de rein

Baptiste DEMEY

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-20) Criblage cellulaire haut débit pour l'identification de molécules inhibant l'infection par le polyomavirus humain BK

Caroline LAMBERT

3^e Journée Scientifique AGIR, Auditorium CHU Amiens Sud, 7 Octobre 2021.

(S2021-21) Synthèse et étude de 2-hétéroaryl-4-quinolones à activité anti-virulence chez *Pseudomonas aeruginosa* (soutenance de thèse)

Marine Duplantier

UFR Pharmacie, UPJV, 22 Octobre 2021.

(S2021-22) Etude de l'activité antimicrobienne de l'alliage cuivreux AB+® (soutenance de thèse)

Emilie Dauvergne

UFR Pharmacie, UPJV, 24 Novembre 2021.

(S2021-23) Développement d'agents anti-virulence à dualité d'action capables de contrer l'antibiorésistance

Marie Hanot

UFR Pharmacie, UPJV, 9 Décembre 2021.

(S2021-24) Caractérisation moléculaire des systèmes d'efflux chez *Acinetobacter baumannii* et étude de nouveaux inhibiteurs analogues de la 1-(1-naphtylméthyl)-pipérazine (soutenance de thèse)

Morgane Choquet

UFR Pharmacie, UPJV, 17 Décembre 2021.